A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)
Completed · Phase 3
Conditions studied: Coronary Artery Disease
In brief
EVOLVE 48 is a prospective, open label, single arm, multi-center trial. The purpose of this study is to assess the FDA requirement for safety and effectiveness of the SYNERGY 48 mm Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) \> 34 mm and ≤ 44 mm in length (by visual estimate) in native coronary arteries ≥2.5 mm to ≤4.0 mm in diameter (by visual estimate).
Key facts
- Study ID
- NCT03350542
- Run by
- Boston Scientific Corporation
- People needed
- 100
- Starts
- 2018-04-12
- Expected to finish
- 2021-01-08
- Last updated by the study team
- 2021-05-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama at Birmingham — Birmingham, Alabama, United States
- HealthEast St. Joseph's Hospital — Saint Paul, Minnesota, United States
- New York Presbyterian Hospital - Columbia University Medical Center — New York, New York, United States
- Rex Hospital — Raleigh, North Carolina, United States
- Lindner Center for Research and Education at Christ Hospital — Cincinnati, Ohio, United States
- York Hospital — York, Pennsylvania, United States
- Baylor Heart & Vascular Hospital — Dallas, Texas, United States
- The Heart Hospital Baylor Plano — Plano, Texas, United States
- P. Stradins University Hospital — Riga, Latvia
- Auckland City Hospital — Auckland, New Zealand
- North Shore Hospital — Takapuna, New Zealand
- Royal Victoria Hospital — Belfast, United Kingdom
- Golden Jubilee National Hospital — Glasgow, United Kingdom
- Freeman Hospital — Newcastle upon Tyne, United Kingdom
- John Radcliffe Hospital — Oxford, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.